Sarepta Therapeutics’ stock soars 38% after FDA expands use of its Duchenne muscular-dystrophy drug
Sarapeta Therapeutics Inc.’s stock soared 38% in premarket trade Friday, after the biotech said the U.S. regulator has approved an expanded indication of its treatment for the rare muscle disorder Duchenne muscular dystrophy.
